. 2020 Jul 31;10(3):78. doi: 10.3390/jpm10030078

Table 3.

No. of residents using drugs with PGx-based dosing guidelines.

Drug	ATC Code	No. of Residents	CYP	RM	EM	IM	PM
Pantoprazole ²⁾	A02BC02	32	CYP2C19	x
Lansoprazole ²⁾	A02BC03	7	CYP2C19	x
Omeprazole ²⁾	A02BC01	3	CYP2C19	x
Esomeprazole ¹⁾	A02BC05	3	CYP2C19 *
Glimepiride	A10BB12	1	CYP2C9 *
Clopidogrel	B01AC04	42	CYP2C19			x	x
Warfarin	B01AA03	3	CYP2C9	x		x	x
Amiodarone	C01BD01	1	CYP2D6 *
Metoprolol	C07AB02	25	CYP2D6	x		x	x
Carvedilol	C07AG02	2	CYP2D6 *
Atenolol	C07AB03	1	CYP2D6 *
Bisoprolol	C07AB07	1	CYP2D6 *
Tramadol	N02AX02	12	CYP2D6	x		x	x
Oxycodone	N02AA05	5	CYP2D6 *
Codeine	R05DA04	8	CYP2D6	x		x	x
Quetiapine	N05AH04	25	CYP2D6 *
Olanzapine	N05AH03	9	CYP2D6 *
Risperidone	N05AX08	4	CYP2D6 *
Aripiprazole	N05AX12	2	CYP2D6				x
Haloperidol ⁴⁾	N05AD01	1	CYP2D6	x			x
Citalopram ^2,4)	N06AB04	24	CYP2C19	x			x
Sertraline ⁴⁾	N06AB06	22	CYP2C19				x
Mirtazapine	N06AX11	17	CYP2D6 *
Amitriptyline	N06AA09	7	CYP2D6	x		x	x
Amitriptyline	-		CYP2C19			x	x
Venlafaxine	N06AX16	5	CYP2D6	x		x	x
Escitalopram ^2,4)	N06AB10	2	CYP2C19	x		x	x
Duloxetine ³⁾	N06AX21	2	CYP2D6 *
Fluoxetine ³⁾	N06AB03	1	CYP2D6 *
Nortriptyline	N06AA10	1	CYP2D6	x		x	x
				L-F	IM-F	N-F
Simvastatin	C10AA01	30	SLCO1B1	x	x
Atorvastin	C10AA05	12	SLCO1B1	x	x

The table displays all drugs used by the residents for which there exists PGx-based dosing guidelines either actionable (AG) or non-actionable (N-AG; marked with *). Drugs with AG are displayed according to phenotype actions (i.e., dose adjustment, dose monitoring or avoidance of the drug). RM: rapid metabolizer, EM: extensive (normal) metabolizer, IM: intermediate metabolizer and PM: poor metabolizer. Drugs are grouped based on their ATC codes. Amitriptyline have AG for both CYP2C19 and CYP2D6. L-F, IM-F and N-F are low, intermediate or no function of the SCLO1B1 transporter. ¹⁾ strong and ²⁾ weak inhibitor of CYP2C19; ³⁾ strong to moderate and ⁴⁾ weak inhibitor of CYP2D6 according to Flockhart [29].